2. Anti-infection
  3. SARS-CoV
  4. Beludavimab

Beludavimab  (Synonyms: BMS 4182137; VIR 7832)

Cat. No.: HY-P99467

Molarity Calculator

Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM.

For research use only. We do not sell to patients.

Beludavimab Chemical Structure

Beludavimab Chemical Structure

CAS No. : 2423016-74-2

Size Stock
1 mg Get quote
5 mg Get quote

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Beludavimab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Beludavimab (BMS 4182137; VIR 7832) is a monoclonal antibody targeting the spike glycoprotein of SARS-CoV-2. Beludavimab binds to recombinant spike protein receptor-binding domain (S-RBD) with an EC50 value of 14.9 ng/mL and a Kd of 0.21 nM[1].

In Vitro

Beludavimab (VIR 7832) targets an epitope containing a glycan (at position N343) that is highly conserved within the Sarbecovirus subgenus in a region of the S receptor binding domain (RBD) that does not compete with angiotensin converting enzyme 2 (ACE2) binding. Beludavimab possesses an Fc “LS” mutation that confers extended half-life by binding to the neonatal Fc receptor[1].
Beludavimab induces NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) in cells from donors expressing the low-affinity F/F158 allele of FcγIIIa more efficiently. Beludavimab neutralizes wild-type and variant pseudotyped viruses and authentic virus in vitro[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Beludavimab Related Antibodies
Clinical Trial
CAS No.
SMILES

[Beludavimab]
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Beludavimab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Beludavimab2423016-74-2BMS 4182137 VIR 7832BMS4182137BMS-4182137VIR7832VIR 7832VIR-7832SARS-CoVSARS coronavirusSARS-CoV-2S-RBDFcmonoclonal antibodyInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Beludavimab
Cat. No.:
HY-P99467
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.